Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy, pharmacokinetics, pharmacodynamics, and safety of OPC-41061 in
patients with chronic renal failure who are undergoing peritoneal dialysis, using daily urine
volume, body weight, and edematous conditions as parameters and conducting dose escalation
every 2 days until reaching the dose that achieves urine volume increase and then performing
5-day repeated administration at the fixed dose, the final dose used in the dose escalation
period.